Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
May 15 2024 - 9:09AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
15 May 2024 15:00 BST
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 13 May 2024, Pascal
Soriot, Chief Executive Officer, was granted an award of the
Company's ordinary shares of $0.25 each (Ordinary Shares) under the
terms of the AstraZeneca Performance Share Plan (AZPSP), as
detailed in the table below.
This award forms part of the AZPSP award granted to Mr Soriot on 4
March 2024. As described in AstraZeneca's 2023 Directors'
Remuneration Report, it has been made in accordance with the
Directors' Remuneration Policy and amended rules of the AZPSP
approved by shareholders at the Company's 2024 Annual General
Meeting.
|
PDMR
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
|
Pascal
Soriot
|
29,474
|
£100.81
|
The AZPSP award is subject to a combination of performance measures
focused on scientific, commercial, financial and sustainability
performance. The performance measures will be assessed over a
three-year performance period (1 January 2024 to 31 December 2026).
The Ordinary Shares granted under the AZPSP are subject to a
two-year holding period following the performance period, and are
due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award can
be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2023, which is
available on the Company's website at www.astrazeneca.com/annualreport2023.
Further details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018).
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Pascal
Soriot
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief
Executive Officer
|
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca
PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Grants
of share awards under the AstraZeneca Performance Share
Plan
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£100.81
|
29,474
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
e)
|
Date of the transaction
|
13 May
2024
|
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
15 May 2024
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From May 2024 to Jun 2024
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From Jun 2023 to Jun 2024
